Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lasmiditan

- PMLiVE

Lilly stops tabalumab trial in arthritis on efficacy grounds

Will take a charge of around $20m to $35m

- PMLiVE

Lilly plans another trial for Alzheimer’s hope solanezumab

Presses on with another late-stage study for the drug

- PMLiVE

New UK managing director for Lilly

Dr Jean-Michel Cossery takes over from Ramona Sequeira

- PMLiVE

Lilly taps Strides Arcolab for cancer generics

Aims to expand its presence in emerging pharmaceutical markets

- PMLiVE

Merz, Lilly and Daiichi-Sankyo breach ABPI code

Pharma companies 'named and shamed' for inappropriate marketing in the UK

- PMLiVE

J&J, Lilly and Merck join forces on clinical trials

Will set up database to improve efficiency of industry-sponsored drug trials

- PMLiVE

Lilly takes Xeljanz rival baricitinib into phase III

Its partner Incyte says baricitinib could become the number one JAK inhibitor for RA

- PMLiVE

Lilly launches diabetes partnership programme in South Africa

Partners with Project Hope and Donald Woods Foundation

- PMLiVE

Lilly’s Cialis cleared for BPH in Europe

Opens up a lucrative new market for the ED drug

- PMLiVE

Lilly promotes Melissa Barnes to chief ethics and compliance officer

Will replace Anne Nobles who retires at the end of 2012

- PMLiVE

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

- PMLiVE

Lilly revenues down as generics erode Zyprexa sales

Sales of antipsychotic drug fall 68 per cent during third quarter

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links